000 01129 a2200325 4500
005 20250517120930.0
264 0 _c20170505
008 201705s 0 0 eng d
022 _a1744-8409
024 7 _a10.1080/1744666X.2016.1246957
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGalluzzo, M
245 0 0 _aBrodalumab for the treatment of psoriasis.
_h[electronic resource]
260 _bExpert review of clinical immunology
_cDec 2016
300 _a1255-1271 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal
_xpharmacology
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aClinical Trials as Topic
650 0 4 _aHumans
650 0 4 _aPsoriasis
_xdrug therapy
650 0 4 _aReceptors, Interleukin-17
_ximmunology
650 0 4 _aTreatment Outcome
700 1 _aD'adamio, S
700 1 _aBianchi, L
700 1 _aTalamonti, M
773 0 _tExpert review of clinical immunology
_gvol. 12
_gno. 12
_gp. 1255-1271
856 4 0 _uhttps://doi.org/10.1080/1744666X.2016.1246957
_zAvailable from publisher's website
999 _c26497385
_d26497385